H.C. Wainwright initiated coverage on GRI Bio with a new price target
$GRI
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $10.00 | Buy | H.C. Wainwright |
4 - GRI Bio, Inc. (0001824293) (Issuer)
4 - GRI Bio, Inc. (0001824293) (Issuer)
4 - GRI Bio, Inc. (0001824293) (Issuer)
Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at 3:00 PM ET on Tuesday, September 9, 2025 at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY. In addition to the presentation, management will be available to participate in in-person one-on-one meetings wit
Live video webcast on Wednesday, August 20th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:20 PM ETPresenter: Marc Hertz, PhD, President, Chief Executive Officer and DirectorRegistration Link: HERE About Webull Financial
Access the "What This Means" segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company's recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis ("IPF"). The "What This Means" segment can be accessed here. Ab
8-K - GRI Bio, Inc. (0001824293) (Filer)
424B3 - GRI Bio, Inc. (0001824293) (Filer)
10-Q - GRI Bio, Inc. (0001824293) (Filer)
H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce